A double-blind, randomised study on the effects of STW 5 on symptoms and immunologic function in patients with irritable bowel syndrome

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000085279

Enrollment

Registered

2009-02-06

Start date

2007-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study is designed to provide information about the way the gastroinstestinal tract responds to the treatment of herbal medication Iberogast.We seek to determine the effects of Iberogast on symptoms and stool frequencey as well as immunologic function.

Interventions

This is a cross over study examining the effects of a herbal preperation, Iberogast (STW 5) and placebo for patients suffering from Irritable Bowel Syndrome compared to healthy controls. Iberogast is a liquid consisting of 9 plant extracts. Each treatment arm is conducted over 2 weeks. Study medication is administered at 20 drops 3 times per day, orally. With a washout period of 1 week between treatment arms.

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

Symptoms consitent with IBS according to the Rome III criteria; Not recieved antibiotics 8 wks prior; Not taking immunosuppressive medications;No Laxatives, no prokinetic drugs for 2 weeks; Able to sign consent

Exclusion criteria

Previous abdominal or gynaecological surgery (except appendectomies and cholecystectomies) previous gastrointestinal cancer;Known peptic ulcers;pregnancy or breastfeeding;chronic inflammatory disease, cardiovascular disease; respiratory disease;Diabetes mellitus; Epilepsy;

Outcome results